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between rodents and human beings have suggested the
need for a large animal model of CAV. To this end, a
heterotopic heart transplantation system has been devel-
oped and validated to study the pathogenesis and treat-
ment of CAV in partially inbred miniature swine.1 In
E xperimental studies investigating the mechanismsand treatment of cardiac allograft vasculopathy
(CAV) have been primarily performed in rodents.
Although these studies have yielded many important
findings, the profound biologic differences that exist
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contrast to the profound differences between rodents
and human beings, the immune system and cardiovas-
cular system of swine closely resemble those of human
beings,2,3 as does their susceptibility to nontransplant4
and transplant atherosclerosis.5
In contrast to rodent systems,6-8 major histocompati-
bility complex (MHC) class I antigens appear to play
an important role in the early development of vascular
lesions in miniature swine.1,9 Thus, when MHC class
I–disparate hearts were transplanted into porcine recip-
ients treated with a short course of cyclosporine A
(INN: ciclosporin; CyA), they all experienced the florid
intimal proliferation of CAV by postoperative day
(POD) 28 and went on to full rejection within 55
days.10 To determine whether the induction of tolerance
to donor class I antigens in the host could prevent the
development of CAV, porcine recipients were cotrans-
planted with the heart and kidney from the same class I
disparate donor. The rationale for this approach grew
out of earlier studies showing that in contrast to heart
allografts CyA-treated recipients bearing isolated class
I disparate kidneys all became tolerant to donor antigen
and maintained excellent long-term renal function.11,12
When miniature swine were cotransplanted with the
heart and kidney from the same class I disparate donor,
they experienced rapid and stable tolerance to the donor
that not only led to the long-term survival of the heart
allografts but also avoided the development of CAV,
thus demonstrating that acquired tolerance can prevent
chronic rejection in this large animal model.10
The mechanism by which tolerance is induced in
porcine recipients of heart plus kidney allografts and
how this acquired tolerance prevents the development
of CAV remains unclear. One hypothesis is that the
donor kidney induces or transfers specific regulatory
T cells to the host, which act centrally, peripherally, or
both to induce tolerance.13 A competing hypothesis is
that the kidney allograft simply confers more donor
antigen to the host and that this augmentation of
donor antigen results in antigen-induced specific
unresponsiveness.14 To determine whether the benefi-
cial effects of donor kidney cotransplantation on car-
diac allograft survival was due to an effect specific to
the kidney graft or to an increase in total donor anti-
gen load, we compared recipients receiving heart and
kidney allografts to recipients transplanted with two
class I disparate hearts or to recipients receiving
donor peripheral mononuclear cells at the time of iso-
lated heart transplantation. We present data here indi-
cating that although augmentation of donor-antigen
load is important, it does not appear to be the sole
mechanism by which transplantation of a kidney
induces tolerance to a heart allograft and thereby pre-
vents CAV. 
Methods
Animals. Partially inbred miniature swine (age, 4-10
months; weight, 20-50 kg) were used as transplant donors
and recipients. The characteristics of miniature swine have
been described previously.15 Recombinant SLAgg (class
Ic/IId) swine were used as heart and kidney donors, and
SLAdd (class Id/IId) animals were used as recipients to
achieve a 2-haplotype MHC class I mismatch.10 All recipients
demonstrated significant in vitro antidonor cytotoxic activity
(>20% specific lysis) before organ transplantation. All animal
care and procedures were in compliance with the “Principles
of Laboratory Animal Care” formulated by the National
Society for Medical Research and the “Guide for the Care
and Use of Laboratory Animals” prepared by the Institute of
Laboratory Animal Resources, National Research Council,
and published by the National Academy Press, revised 1996.
Surgical procedures. A semipermanent indwelling sili-
cone rubber central venous catheter was placed into the exter-
nal jugular vein of recipients to facilitate CyA administration
and frequent blood sampling for monitoring of renal function,
whole blood CyA levels, and in vitro assays. The surgical pro-
cedures used for heart transplantation, kidney transplantation,
and combined heart-kidney transplants have been described
in detail previously.1,10,16 Juvenile donors and recipients were
anesthetized with ketamine (20 mg/kg), halothane 1%, nitrous
oxide 1%, and oxygen. Through either a retroperitoneal or
transperitoneal approach, the infrarenal aorta and inferior
vena cava were isolated. After the recipient had been system-
ically heparinized (3 mg/kg), heterotopic heart transplantation
was performed on the right side of the great vessels by anas-
tomosing the donor pulmonary artery end to side to the recip-
ient inferior vena cava and then anastomosing the donor
ascending aorta end to side to the recipient abdominal aorta.
An atrial septal defect was created in the donor heart, and the
mitral valve was defunctionalized to minimize left ventricular
atrophy and intracavitary thrombus formation.17 Iridium-
tipped ventricular electrodes (model 6500 pacing lead;
Medtronic Inc, Secaucus, NJ) were implanted in the
myocardium of each ventricle and brought out through the
skin for long-term electrocardiographic monitoring. In some
cases, heart transplantation was followed by transplantation
of a kidney (combined heart-kidney transplant) or a second
heart (double-heart transplant) 1 to 2 cm below the cardiac
allograft on the left. After blood flow to the cardiac allograft
had been re-established, kidney transplantation was per-
formed by anastomosing the donor renal artery end to side to
the recipient aorta and then anastomosing the donor renal vein
end to side to the recipient inferior vena cava below the level
of the heart allograft. The renal transplant was completed by
performing a vesicoureteral anastomosis. The second heart
was transplanted in the manner described above. Two SLAgg
donors were used for each double-heart transplant recipient
(SLAdd). In some cases a total thymectomy, described in
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detail elsewhere,13 was carried out through a median ster-
notomy 21 days before double-heart transplantation.
Peripheral blood leukocyte leukopheresis and infusion.
Peripheral blood leukocytes (PBLs) were obtained from donor
animals by using the COBE Spectra Apheresis System (serial
No. 1S03226; COBE BCT Inc, Lakewood, Colo). Two semi-
permanent silicone rubber central venous catheters were
placed in the internal jugular veins for venous access. A total
of 3 blood volumes were circulated through the system, which
yielded an average volume of 244 mL of PBLs. Three milli-
liters of the cell suspension was removed, washed in Hanks’
buffered saline solution (HBSS), and counted after diluting
with trypan blue stain. In some recipients 2.5 × 109 fresh donor
PBLs per kilogram (recipient body weight) were infused intra-
venously immediately after the heart transplant procedure had
been completed and hemostasis had been obtained.
Immunosuppression. CyA (Sandimmune) was generously
provided by Novartis Pharmaceutical Corporation (Hanover,
NJ) and was mixed and administered as an intravenous sus-
pension according to the specifications of the manufacturer.
CyA was given daily as a single infusion at a dose of 10 to 13
mg/kg (adjusted to maintain a whole blood trough level of
400-800 ng/mL) for 12 consecutive days, starting on the day
of transplantation (POD 0). CyA levels were determined by
means of a fluorescence polarization immunoassay (Abbott
Laboratories, North Chicago, Ill), which measured parent
compound but not metabolites.
Rejection monitoring. Heart function was monitored by
using transabdominal palpation, electrocardiography
(EK/5A, Burdick Corp, Milton, Wis), and echocardiography
(Sonos 1500; Hewlett-Packard Company, Andover, Mass).
Kidney function was monitored by means of serum creatinine
levels. Cardiac allograft rejection (heart survival time) was
defined by either the loss of a ventricular impulse on palpa-
tion, an R-wave amplitude of less than 3 mm on epicardial
electrocardiography, and/or the lack of ventricular contrac-
tion on echocardiography.1 Renal allograft rejection was
defined as the death (or need for euthanasia) of the recipient
because of terminal uremia. Allograft rejection was con-
firmed histologically in all cases.
Histology. Sequential heart, kidney, or both types of allo-
graft biopsies were performed on PODs 8, 14, 18 to 21, 28 to
30, 50, and >100. Open biopsy specimens of the transplanted
heart and kidney were obtained by using a Tru-Cut needle
(Baxter, Deerfield, Ill) or wedge biopsies. Coded histologic
specimens were stained by using hematoxylin and eosin,
Masson’s trichrome, and periodic acid–Schiff staining and
scored under light microscopy by a blinded observer to deter-
mine the severity of acute rejection and the degree of intimal
proliferation. Scoring of acute rejection in the heart allograft
was based on the International Society for Heart and Lung
Transplantation classification.18 The degree of arterial intimal
thickening was scored from 0 (normal artery) to 3 (>50%
luminal occlusion) on the basis of a modification of the sys-
tem described by Lurie and colleagues.1,19 The average grade
of intimal thickening of all small, medium, and large arterial
vessels examined from each heart at necropsy was designat-
ed the mean average involvement score6 and recorded.
Kidney allograft rejection was scored by means of standard
pathologic criteria described elsewhere.20 Heart and kidney
biopsy specimens were also evaluated for alloantibody depo-
sition by direct immunofluorescence staining. Frozen tissue
sections were stained with a saturating concentration of a flu-
orescence isothiocyanate (FITC)–labeled goat anti-swine
immunoglobulin (Ig) M or IgG and evaluated by fluorescence
microscopy.
Preparation of PBLs for in vitro assays. Freshly
heparinized whole blood was diluted approximately 1:2 with
HBSS (Gibco BRL, Grand Island, NY), and the mononuclear
cells were obtained by means of gradient centrifugation with
lymphocyte separation medium (Organon; Teknika, Durham,
NC). The mononuclear cells were washed once with HBSS,
and contaminating red cells were lysed with ammonium chlo-
ride potassium lysing buffer (Bio Whittaker, Inc,
Walkersville, Md). Cells were then washed with HBSS and
resuspended in tissue culture medium. All cell suspensions
were kept at 4°C until used in cellular assays. 
Cell-mediated lymphocytotoxicity assay. Cell-mediated
lymphocytotoxicity (CML) assays with porcine cells have
been described previously.21 The tissue culture media used
for the CML assays consisted of RPMI-1640 (Gibco BRL)
supplemented with 6% fetal calf serum (Sigma Chemical Co,
St Louis, Mo), 100 U/mL penicillin, 135 mg/mL strepto-
mycin (Gibco BRL), 50 mg/mL gentamicin (Gibco BRL), 10
mmol/L N–2-hydroxyethylpiperazine-N-2-ethanesulfonic
acid (HEPES; Fisher Scientific, Pittsburgh, Pa), 2 mmol/L L-
glutamine (Gibco BRL), 1 mmol/L sodium pyruvate (Bio
Whittaker, Inc), nonessential amino acids (Bio Whittaker,
Inc), and 5 × 10–5 mol/L β2-mercaptoethanol (Sigma
Chemical). The effector phase of the CML assay was per-
formed with Basal Medium Eagle (Gibco BRL) supplement-
ed with 6% controlled processed serum replacement 3
(Sigma Chemical) and 10 mmol/L HEPES. Briefly, lympho-
cyte cultures containing 4 × 106/mL responder and 4 ×
106/mL stimulator PBLs (irradiated with 2500 cGy) were
incubated for 6 days at 37° in 7.5% carbon dioxide and 100%
humidity in CML medium. Bulk cultures were harvested, and
effectors were tested for cytotoxic activity on chromium
51–labeled (Amersham, Arlington Heights, Ill) lymphoblast
targets. Effector cells were incubated for 5.5 hours with tar-
get cells at effector/target ratios of 100:1, 50:1, 25:1, and
12.5:1. Three target cells were tested in each assay: (1) PBLs
SLA matched to the responders (negative control), (2) PBLs
SLA matched to the donor (SLAgg: class Icc and class IIdd),
and (3) third-party PBLs. Supernatants were then harvested
by using the Skatron collection system (Skatron, Sterling,
Va), and 51Cr release was determined on a gamma counter
(Micromedics, Huntsville, Ala). The results were expressed
as a percentage of specific lysis and calculated as follows:
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Percentage of specific lysis = 
Experimental release (cpm) – Spontaneous release (cpm)
Maximum release (cpm) – Spontaneous release (cpm)       × 100
Flow cytometry. The presence of antidonor class I (SLA
class Icc) IgM and IgG in the serum of swine was detected by
means of indirect flow cytometry with a Becton Dickinson
FACScan microfluorimeter (Sunnyvale, Calif) by using
recombinant SLA PBLs to determine the SLA-binding speci-
ficity of the antibody. FITC-labeled goat anti-swine IgM or
IgG polyclonal antibodies were used as secondary reagents
(Kirkegaard & Perry Laboratories Inc, Gaithersburg, Md).
For staining, 1 × 106 cells per tube of donor-type PBLs
(SLAgg, class Ic and IId) were resuspended in HBSS contain-
ing 0.1% bovine serum albumin and 0.05% NaN3 and incu-
bated for 30 minutes at 4°C with decomplemented test sera.
After two washes, a saturating concentration of FITC-labeled
goat anti-swine IgM or IgG was added and incubated for 30
minutes at 4°C. After a final wash, cells were analyzed by
means of flow cytometry with propidium iodide gating to
exclude dead cells. Both normal pig serum and pretransplant
sera from each experimental animal were used as controls for
specific binding.
Circulating donor cells were also evaluated to assess donor
macrochimerism by using flow cytometry with whole blood
from the recipient. Cells were stained with optimal concen-
trations of directly conjugated anti-pig murine monoclonal
antibodies (mAbs) 74-12-4 (IgG2b, anti-swine CD4), 76-2-
11 (IgG2a, anti-swine CD8), 76-7-4 (IgG2a, anti-swine
CD1),22 MSA4 (IgG2a, anti-swine CD2),23 2-6-15 (IgG2a,
anti-swine CD3; C. Huang, manuscript in preparation), 2-27-
3a (IgG2a, anti-swine class I), ISCR-3 (IgG2a, anti-swine
class II), and 16.7 (IgM, anti-SLA class Ic). Phenotype was
analyzed by 2-color staining. The staining procedure was per-
formed as follows. One hundred microliters per tube of
heparinized whole blood was incubated for 30 minutes at 4°C
with saturating concentrations of an FITC-labeled mAb.
After a single wash, the secondary biotinylated antibody was
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Table I. Graft survival, interstitial rejection, and intimal thickening in donor cardiac allografts
Histology
Animal 
Group Thymectomy identification No. Rejection 3 wk 4 wk 9 wk >12 wk PM§ Survival (d)
Isolated heart No 11065* Vascular† 3 3 35
Interstitial‡ 4 4
11613* Vascular 1 1 33
Interstitial 3b 3b
11168* Vascular 1 3 45
Interstitial 2 3a
11749* Vascular 2 3 55
Interstitial 1b 3b
11776* Vascular 2 3 47
Interstitial 3a 4
Heart and kidney No 11982* Vascular 0 0 0 0 >179
Interstitial 1b 1a 1a 1a
12232* Vascular 0 0 0 0 >269
Interstitial 1a 0 0 0
12333* Vascular 0 0 0 0 >261
Interstitial 1b 0 0 0
12614 Vascular 0 0 0 >200
Interstitial 0 0 0
Double heart No 12240 Vascular 1 1 1 1 >190
Interstitial 2a 2a 1a 1a
12366 Vascular 1 1 2 2 >197
Interstitial 3a 2a 1a 1a
Yes 12688 Vascular 3 3 63
Interstitial 4 4
12949 Vascular 3 2 2 96
Interstitial 3a 3b 4a
Heart and PBL No 12922 Vascular —II 1 1 63
Interstitial 3a 4 4
12952 Vascular — 2 2 47
Interstitial 3b 3b 3b
*The results of these control animals have been reported previously.10
†Small and large arteries were graded on the basis of a scoring system modified from that of Lurie and colleagues.19 The average score of all involved vessels was
rounded to the nearest whole number.
‡Grading on the basis of the International Society for Heart and Lung Transplantation scoring system.18
§Represents either the most recent biopsy or the necropsy specimen.
IIInsufficient number of arteries in specimen.
added, and cells were incubated for 30 minutes at 4°C. After
a further wash, phycoerythrin-streptavidin was added and
incubated for 10 minutes to stain the biotinylated antibody.
Two milliliters of 1× FACS lysing solution (Becton
Dickinson) was then added to each tube to lyse red blood
cells. The tubes were placed in a vortex and then incubated
for 10 minutes at room temperature. The tubes were then
placed in a vortex once more to ensure complete lysis of red
blood cells before centrifugation. The cells were washed once
and analyzed by FACScan.
Results
The effect of double-heart transplantation on
tolerance and CAV. We10 have previously reported
that isolated heart allografts transplanted across a
class I disparity in miniature swine treated with a 12-
day course of CyA (POD 0-11) had florid coronary
intimal proliferation by POD 28 and were rejected by
POD 55 (Table I). In contrast, hearts cotransplanted
with a kidney from the same class I disparate donor
survived long term without the development of vascu-
lar lesions (Table I).10 To determine whether the spe-
cific unresponsiveness to heart allografts induced by
combined heart-kidney cotransplantation was due to
an increase in donor antigen load or to an effect spe-
cific to the kidney allograft, we performed double-
heart transplantation. Each recipient received two
hearts that were MHC matched to each other but class
I mismatched to the host.
The two recipients of double-heart allografts that
were not thymectomized (Nos. 12240 and 12366) main-
tained their allografts long term (later than POD 190
and 197, respectively), which was similar to euthymic
heart-kidney recipients (Table I). However, marked dif-
ferences were observed between euthymic double-heart
recipients and euthymic heart-kidney recipients in the
development of in vitro parameters of alloresponsive-
ness and occurrence of both acute and chronic rejection
histologically. Whereas heart-kidney recipients lost
antidonor cytotoxic T lymphocyte (CTL) reactivity by
POD 30, the euthymic double-heart recipients main-
tained antidonor CTL reactivity long term (Fig 1). Both
euthymic double-heart recipients had antidonor IgM
between PODs 20 and 30 (data not shown), whereas
heart-kidney recipients never had a humoral allore-
sponse.10 Heart-kidney recipients never had significant
interstitial rejection of either allograft and never had
CAV. However, both heart allografts in euthymic dou-
ble-heart recipients showed moderate interstitial
mononuclear cell infiltrate by POD 60 and exhibited
significant CAV by POD 30 (Table I and Fig 2, A).
Previous studies from our laboratory have suggested
that the thymus plays a critical role in the induction of
tolerance in miniature swine.13,24 To determine whether
the prolongation of cardiac allograft survival in the
double-heart recipients was dependent on the thymus,
complete thymectomy was performed 3 weeks before
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Fig 1. Antidonor CTL reactivity in euthymic double-heart recipients (right two columns) and representative data
of antidonor CTL reactivity in a heart-kidney recipient (left column). E:T ratio, Effector cell/target cell ratio.
transplantation in two double-heart recipients (Nos.
12688 and 12949). In contrast to euthymic recipients,
both thymectomized double-heart recipients had rejec-
tion of their heart grafts in less than 100 days (PODs 63
and 96, respectively; Table I). The stronger allore-
sponses mounted by thymectomized double-heart
recipients was reflected in in vitro studies and graft his-
tology. At necropsy, cardiac allografts from thymec-
tomized double-heart recipients demonstrated a greater
degree of intimal proliferation in both large and small
vessels compared with hearts removed from euthymic
double-heart recipients at necropsy (Table I and Fig 2,
B). The thymectomized double-heart recipients also
exhibited stronger antidonor CTL responses after trans-
plantation than the euthymic double-heart recipients
(compare Fig 1 and Fig 3). Finally, allo-IgG antibody
deposition on the endothelium of small donor coronary
arteries from the rejected allografts of thymectomized
double-heart recipients was more extensive than that
seen on the coronary endothelium from rejected allo-
grafts of euthymic double-heart recipients (Fig 2, C).
These data suggest that the host thymus plays an
important role in the prolongation of graft survival in
recipients of double-heart transplantation and corrobo-
rates earlier studies that demonstrated the important
role the thymus plays in rejection responses in minia-
ture swine.13,24
The effect of donor PBL infusion on tolerance and
CAV. We next investigated whether the augmentation
in donor antigen load conferred by a high-dose infusion
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Fig 2. Representative histologic findings of MHC class I disparate heart grafts of recipients bearing double-heart
grafts. A, A euthymic recipient on POD 60 exhibited moderate mononuclear cell infiltration along with CAV
(hematoxylin and eosin staining). B, A thymectomized recipient on POD 63 exhibited severe mononuclear cell
infiltration along with development of CAVs (hematoxylin and eosin staining). C, Immunohistochemical analy-
sis of the deposition of IgG alloantibodies on the endothelium of coronary arteries in transplanted hearts in a
thymectomized recipient on POD 63 (anti-swine IgG FITC). D, Histologic findings of MHC class I disparate
heart graft of single-heart recipients with high-dose donor PBL infusion exhibited moderate mononuclear cell
infiltration along with CAV on postoperative day 47 (hematoxylin and eosin staining).
A B
C D
of donor PBLs could prolong allograft survival in
euthymic recipients of isolated class I disparate hearts.
Two recipients (Nos. 12952 and 12922) received class
I–mismatched isolated heart allografts along with an
intravenous infusion of fresh donor PBLs (2.5 ×
109/kg) on POD 0. Donor lymphocyte macrochimerism
was assessed by means of FACS with a donor SLA
class I–specific mAb. Both recipients exhibited high
levels of macrochimerism during the period of CyA
administration (PODs 0-12; Fig 4). However, the levels
of macrochimerism declined shortly thereafter and
were undetectable by POD 33. The majority of donor
cells in the lymphocyte gate were CD3+ T cells (Fig 4,
dashed line). Further phenotypic analysis demonstrated
that both CD4+ T cells and CD8+ T cells were present
in the early period (<14 days; Fig 5, A). However, by
POD 26, only 0.1% of donor T cells expressed the CD4
marker (Fig 5, B). In addition, 70% of donor lympho-
cytes on POD 26 were CD3+/CD2–, suggesting that
these were γδ T cells (Fig 5, B).
Hearts transplanted into recipients treated with high-
dose donor PBLs had high-grade interstitial rejection
and were fully rejected by PODs 47 and 63 (Table I).
At necropsy, extensive mononuclear cell infiltrates
were observed in the heart allografts from both recipi-
ents. One animal exhibited marked CAV, and the other
exhibited severe endotheliitis (Table I). Both recipients
had antidonor class I IgM and IgG by the time of rejec-
tion (data not shown). Although both recipients lost
donor-specific responsiveness in CML assays on POD
30, by the time of allograft rejection, both recipients
had regained antidonor CTL reactivity (Fig 6). These
data indicate that augmentation of donor antigen load
by high-dose donor PBL infusion and achieving a state
of high-level, albeit short-lived, peripheral macro-
chimerism were not as effective as donor kidney
cotransplantation in prolonging cardiac allograft sur-
vival and preventing CAV.
Discussion
We10 have previously reported that when cardiac
allograft recipients were simultaneously cotransplanted
with a donor-specific kidney graft, the hosts became
tolerant to both allografts. Furthermore, the state of tol-
erance that resulted from heart-kidney cotransplanta-
tion not only led to long-term survival of the heart allo-
grafts but also prevented the development of CAV. One
hypothesis to explain the tolerogenic effect of the kid-
ney allograft is that specialized cells (possibly bone
marrow–derived dendritic cells) residing in the kidney
migrate to the thymus, where they induce and maintain
tolerance. This could occur either by means of central
deletional mechanisms (ie, donor dendritic cells or host
antigen-presenting cells with donor antigen migrating
to the thymus and educating host T-cell precursors or
reeducating mature circulating T cells)25 or peripheral
mechanisms (ie, thymic-derived, host regulatory cells
that traffic back to the allograft and mediate local sup-
pression). According to this hypothesis, a heart allo-
graft alone would not induce unresponsiveness because
it does not have sufficient numbers of these
immunoregulatory cells.
An alternative hypothesis is that cotransplantation of
the kidney allograft simply augments the load of donor
antigen presented to the host at the time of heart trans-
plantation and results in antigen-induced unresponsive-
ness, which is similar to the “blood transfusion
effect.”14 To address this issue, we compared heart-kid-
ney transplantation with double-heart transplantation.
We demonstrated that, like recipients bearing a heart
and kidney, recipients bearing two hearts accepted their
allografts over the long term. However, unlike heart-
kidney recipients, the double-heart recipients main-
tained antidonor CTL reactivity, had alloantibodies,
and had significant CAV, indicating that tolerance had
not been achieved. One interpretation of these results is
that an augmentation in donor antigen load was able to
effectively delay acute rejection but that a kidney-relat-
ed mechanism was necessary for inducing rapid and
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Fig 3. Antidonor CTL reactivity in thymectomized double-
heart recipients. E:T ratio, Effector cell/target cell ratio.
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Fig 4. Flow cytometric analysis of lymphopoietic donor macrochimerism in whole blood from recipients bearing
an isolated class I disparate heart allograft after high-dose donor PBL infusion.
Fig 5. Phenotypic analysis of donor chimerism by FACS in the recipient (No. 12922) bearing MHC class I dis-
parate isolated heart allograft with high-dose donor PBL infusion. A, CD4+ cells or CD8+ donor cells were seen
on POD 4. B, Only 0.1% of donor T cells expressed CD4, and 70% of donor lymphocytes were CD3+/CD2– cells
on POD 26.
A
B
stable tolerance and preventing the vascular lesions of
chronic rejection. The inability of high-dose donor
leukocyte infusion to facilitate tolerance and prevent
CAV supports this theory.
The protective role that a donor-specific kidney plays
in cardiac allograft survival has been reported in both
experimental10 and clinical transplantation,26 but the
mechanisms underlying this effect have not been eluci-
dated. As we mentioned above, one hypothesis to
explain the tolerogenic effect of the kidney allograft is
that renal parenchyma contains a greater number of
regulatory cells (possibly dendritic cells–passenger
leukocytes) that can migrate from the donor kidney to
the host thymus and mediate central tolerance. Support
for this theory comes from the fact that thymectomiz-
ing recipients of isolated kidney allografts13 or heart-
kidney allografts24 prevented the induction of rapid and
stable tolerance. However, in the present study double-
heart recipients that were thymectomized exhibited a
more aggressive rejection response than euthymic dou-
ble-heart recipients, despite the absence of a donor kid-
ney. Similarly, we have previously shown that single-
heart recipients that were thymectomized also
exhibited a more aggressive rejection response than
euthymic single-heart recipients.24 In addition, thymec-
tomized heart-kidney recipients had CAV and rejected
their cardiac allografts in a similar fashion to euthymic
single-heart recipients.24 These results suggest that the
detrimental effect thymectomy has on graft survival
may also be related to the loss of recent thymic emi-
grants independent of kidney-specific mechanisms.
These thymic emigrants could represent regulatory
cells, which traffic from the host’s thymus to the donor
organ irrespective of the presence of a kidney allograft,
and induce tolerance peripherally by downregulating
alloreactive cells within the graft. Such peripheral tol-
erance could be mediated by suppressive regulatory
mechanisms, by a change in cytokine milieu, or both.
There is evidence from several groups that the induc-
tion of tolerance by CyA is mediated by regulatory T
cells and requires a functioning thymus.27-29 We have
also demonstrated that the maintenance of tolerance to
renal allografts in our model is associated with the
presence of peripheral regulatory cells.30
To separate the beneficial effects that may be mediat-
ed by kidney-independent recent thymic emigrants
from the effects of kidney-derived cells that traffic to
the host thymus, we plan to perform thymectomy in
heart-kidney recipients on POD 0 instead of 3 weeks
after transplantion. Our hypothesis is that the double-
heart experiments imply an additional role for recent
thymic emigrants, whereas the kidney-heart experi-
ments imply a role for kidney-derived regulatory cells.
If this hypothesis is true, then the difference in survival
times between the double-heart versus single-heart
recipients (most of which is lost when thymectomy is
performed on day –21) should still be seen if thymec-
tomy is performed on day 0, whereas the difference in
survival times between between kidney plus heart ver-
sus single heart alone (most of which is also lost when
thymectomy is performed on day –21) should also be
lost if thymectomy is performed on day 0. To charac-
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Fig 6. Anti-donor CTL reactivity in recipients of isolated class I disparate heart allografts after high-dose donor
PBL infusion. E:T ratio, Effector cell/target cell ratio.
terize the role of kidney-derived cells on the induction
of tolerance to heart allografts, we plan to extract, phe-
notype, and infuse different kidney cell populations
into heart transplant recipients and study their effects
on CAV. Finally, even though augmentation of donor
antigen load did not lead to tolerance, it did prolong
graft survival significantly.
In conclusion, the present study demonstrates that
although an augmentation of donor antigen introduced
into the host at the time of transplantation may have
beneficial effects in suppressing acute rejection, it does
not appear to be the sole mechanism by which cotrans-
plantation of a heart and a kidney induces tolerance.
Other kidney- and thymus-related mechanisms seem to
play an important role in the abrogation of the vascular
lesions of chronic rejection.
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